Doseology Sciences Inc (DOSEF) Fair Value & Analysis
Healthcare · US · Market cap $898K
Doseology Sciences Inc
DOSEF · US
Fair value as of: Jul 31, 2026
From 1 valuation models · updated 10 days ago
Share price −0.6% over the past month.
Below-average quality, screening 37% undervalued on our models.
What matters now
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid quality (45/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range ($0.1020 to $0.1870) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.
How to read this chart
51‑month range $0.0516 – $1.02 · fair‑value band $0.1020 – $0.1870 · the $0.1114 price screens below the $0.1530 fair value. Dashed = 300-day average. As of Jul 31, 2026.
Analysis
Doseology Sciences Inc (DOSEF) currently trades at $0.1114, while our model-based Fair Value estimate is $0.1530, implying the stock looks roughly 37.3% undervalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
The balance sheet holds a net cash position of $1.3M. Fundamentals as of Jul 31, 2026
Our scenario range runs from $0.1020 (bear case) to $0.1870 (bull case); at $0.1114, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 37%, DOSEF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when DOSEF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 1
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures.
Full company description
Doseology Sciences Inc., through its subsidiary, Dose Labs Inc., engages in the research, development, and sale of functional mushroom products with a focus on mental health research in Canada. The company also offers medicinal mushroom products, including tinctures. It sells its products online through doseology.com and e-commerce platforms, as well as through various retail chains and distributors. The company was formerly known as Pcybin Therapeutic Inc. and changed its name to Doseology Sciences Inc. in January 2020. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Doseology Sciences Inc reported revenue of $42.6K in FY2025 versus $0 in FY2021. Reported net income was −$448K in FY2025.
Watch DOSEF: get an alert when its fair value changes →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Doseology Sciences Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Doseology Sciences Inc (DOSEF) overvalued or undervalued?
What is the fair value of DOSEF?
What is the quality score of DOSEF?
What is the net profit margin of DOSEF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Doseology Sciences Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.